EC grants marketing authorisation for IntraBio’s Aqneursa
The European Commission (EC) has granted marketing authorisation for IntraBio’s Aqneursa (levacetylleucine) to treat neurological symptoms of Niemann-Pick disease type…
05 Jun 2026
Parabilis eyes $475m IPO to push lead asset into Phase III
Parabilis Medicines is hoping to raise $475m in an initial public offering (IPO) as it set its sights on the Nasdaq exchange. The proposed IPO will see Parabilis offer 25,000,000…
05 Jun 2026
Pfizer signs licence agreement with Chai for AI drug discovery
Pfizer and Chai Discovery have agreed on a licensing deal enabling the former to incorporate Chai’s AI platform into its drug discovery operations. This partnership provides the biopharmaceutical company with…
05 Jun 2026
Biogen’s salanersen gains FDA breakthrough therapy designation for SMA
Biogen has received the breakthrough therapy designation from the US Food and Drug Administration (FDA) for salanersen (BIIB115), an investigational treatment for spinal muscular atrophy (SMA). This advance recognises preliminary…
04 Jun 2026
Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership
Eli Lilly has penned a research collaboration deal with Massachusetts-based biotech, Ascidian Therapeutics, to discover and develop drugs for kidney diseases – adding another bead to the string of genetic…
04 Jun 2026
Cellares and TScan to assess automated manufacturing of TSC-101 therapy
Cellares and TScan Therapeutics have entered an agreement to examine the use of automated manufacturing for TScan’s TSC-101 therapy in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).…
04 Jun 2026
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies, with the deal’s total potential value rising to up to $4bn.…